Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice
Open Access
- 21 July 2011
- journal article
- clinical trial
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 12 (1) , 167
Abstract
Monitoring osteoporosis therapy by measurement of bone turnover markers (BTMs) might detect non-compliance in an earlier stage of anti-osteoporosis treatment and improve persistence.Keywords
This publication has 19 references indexed in Scilit:
- Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With OsteoporosisJournal of Bone and Mineral Research, 2009
- OsteoporosisThe Lancet, 2006
- Clinical use of serum and urine bone markers in the management of osteoporosisCurrent Medical Research and Opinion, 2005
- Reproducibility of bone mineral density measurement in daily practiceAnnals of the Rheumatic Diseases, 2004
- Compliance with pharmacologic therapy for osteoporosisOsteoporosis International, 2003
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With RisedronateJournal of Bone and Mineral Research, 2003
- Association of baseline levels of markers of bone and cartilage degradation with long‐term progression of joint damage in patients with early rheumatoid arthritisArthritis & Rheumatism, 2002
- III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal OsteoporosisEndocrine Reviews, 2002
- What Is the Role of Serial Bone Mineral Density Measurements in Patient Management?Journal of Clinical Densitometry, 2002
- Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal womenClinical Biochemistry, 2001